Hurley Capital’s ClearPoint Neuro CLPT Stock Holding History

Hurley Capital’s Portfolio CLPT Stock Details CLPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3K	Hold	330	–	–	﹤0.01%	528
2025 Q4	$4.51K	Buy	+330	New	+$6.12K	﹤0.01%	435

Other funds holding CLPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lane Generational Dover, Massachusetts $126M AUM 53.89% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Hurley Capital's CLPT Position: Q1 2026 in Review

Hurley Capital held its ClearPoint Neuro (CLPT) position steady in Q1 2026 at 330 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #528.

Hurley Capital first reported a position in CLPT in Q4 2025 and has held it in 2 quarters since. The position peaked at $4.51K in Q4 2025. 118 funds tracked by Wall St. Rank hold CLPT as of Q1 2026.

Hurley Capital held 330 shares of ClearPoint Neuro worth $3K as of Q1 2026.
Hurley Capital left its ClearPoint Neuro share count unchanged in Q1 2026.
ClearPoint Neuro made up ﹤0.01% of Hurley Capital's portfolio in Q1 2026, its #528 holding.
Hurley Capital first reported a position in ClearPoint Neuro in Q4 2025 and has held it in 2 quarters since.
Hurley Capital's ClearPoint Neuro position peaked at $4.51K in Q4 2025.
118 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.